Thiazolidinediones are Partially Effective Bitter Blockers.

PURPOSE: The bad bitter taste of some medicines is a barrier to overcoming noncompliance with medication use, especially life-saving drugs given to children and the elderly. Here, we evaluated a new class of bitter blockers (thiazolidinediones, TZDs). METHODS: In this study, 2 TZDs were tested, rosiglitazone (ROSI) and a simpler form of TZD, using a high-potency sweetener as a positive control (neohesperidin dihydrochalcone, NHDC). We tested bitter-blocking effects using the bitter drugs tenofovir alafenamide fumarate (TAF), a treatment for HIV and hepatitis B infection, and praziquantel (PRAZ), a treatment for schistosomiasis, by conducting taste testing with 2 separate taste panels: a general panel (N = 97, 20-23 years, 82.5% female, all Eastern European) and a genetically informative panel (N = 158, including 68 twin pairs, 18-82 years, 76% female, 87% European ancestry). Participants rated the bitterness intensity of the solutions on a 100-point generalized visual analog scale. FINDINGS: Person-to-person differences in drug bitterness were striking; TAF and PRAZ were weakly or not bitter for some people but moderately to highly bitter for others. Participants in both taste panels rated the bitter drugs TAF and PRAZ as less bitter on average when mixed with NHDC than when sampled alone. ROSI partially suppressed the bitterness of TAF and PRAZ, but effectiveness differed between the 2 panels: bitterness was significantly reduced for PRAZ but not TAF in the general panel and for TAF but not PRAZ in the genetically informative panel. ROSI was a more effective blocker than the other TZD. IMPLICATIONS: These results suggest that TZDs are partially effective bitter blockers and the suppression efficacy differs from drug to drug, from person to person, and from panel to panel, suggesting other TZDs should be designed and tested with more drugs and on diverse populations to define which ones work best with which drugs and for whom. The discovery of bitter receptor blockers can improve compliance with medication use.

Thiazolidinediones are partially effective bitter blockers.

Purpose: The bad bitter taste of some medicines is a barrier to overcoming non-compliance with medication use, especially life-saving drugs given to children and the elderly. Here we evaluated a new class of bitter blockers (thiazolidinediones; TZDs). Methods: In this study, two TZDs were tested, rosiglitazone (ROSI) and a simpler form of TZD, using a high-potency sweetener as a positive control (neohesperidin dihydrochalcone, NHDC). We tested bitter-blocking effects using the bitter drugs tenofovir alafenamide fumarate (TAF), a treatment for HIV and hepatitis B infection, and praziquantel (PRAZ), a treatment for schistosomiasis, by conducting taste testing with two separate taste panels: a general panel (N=97, 20-23 yrs, 82.5% female, all Eastern European) and a genetically informative panel (N=158, including 68 twin pairs, 18-82 yrs, 76% female, 87% European ancestry). Participants rated the bitterness intensity of the solutions on a 100-point generalized visual analog scale. Findings: Participants in both taste panels rated the bitter drugs TAF and PRAZ as less bitter on average when mixed with NHDC than when sampled alone. ROSI partially suppressed the bitterness of TAF and PRAZ, but effectiveness differed between the two panels: bitterness was significantly reduced for PRAZ but not TAF in the general panel and for TAF but not PRAZ in the genetically informative panel. ROSI was a more effective blocker than the other TZD. Implications: These results suggest that TZDs are partially effective bitter blockers, suggesting other TZDs should be designed and tested with more drugs and on diverse populations to define which ones work best with which drugs and for whom. The discovery of bitter receptor blockers can improve compliance with medication use.

Neural coding of human values is underpinned by brain areas representing the core self in the cortical midline region.

The impact of human values on our choices depends on their nature. Self-Transcendence values motivate us to act for the benefit of others and care for the environment. Self-Enhancement values motivate us to act for our benefit. The present study examines differences in the neural processes underlying these two value domains. Extending our previous research, we used fMRI to explore first of all neural correlates of Self-Transcendence vs Self-Enhancement values, with a particular focus on the putative role of the medial prefrontal cortex (MPFC), which has been linked to a self-transcendent mind-set. Additionally, we investigated the neural basis of Openness to Change vs Conservation values. We asked participants to reflect on and rate values as guiding principles in their lives while undergoing fMRI. Mental processing of Self-Transcendence values was associated with higher brain activity in the dorsomedial (BA9, BA8) and ventromedial (BA10) prefrontal cortices, as compared to Self-Enhancement values. The former involved activation and the latter deactivation of those regions. We did not detect differences in brain activation between Openness to Change vs Conservation values. Self-Transcendence values thus shared brain regions with social processes that have previously been linked to a self-transcendent mind-set, and the "core self" representation.

Neural evidence of motivational conflict between social values.

Motivational interdependence is an organizing principle in Schwartz's circumplex model of social values, which has received abundant cross-cultural support. We used fMRI to test whether motivational relations between social values predict different brain responses in a situation of choice between values. We hypothesized that differences in brain responses would become evident when the more important value had to be selected in pairs of congruent (e.g., wealth and success) as opposed to incongruent (e.g., curiosity and stability) values as they are described in Schwartz's model, because the former serve mutually facilitating motives, whereas the latter serve mutually inhibiting motives. Consistent with the model, choosing between congruent values led to longer response times and more activation in conflict-related brain regions (e.g., the supplementary motor area, dorsolateral prefrontal cortex) than selecting between incongruent values. These results provide novel neural evidence supporting the circumplex model's predictions about motivational interdependence between social values. In particular, our results show that the neural networks underlying social values are organized in a way that allows activation patterns related to motivational similarity between congruent values to be dissociated from those related to incongruent values.

Noradrenaline-induced enhancement of oscillatory local field potentials in the mouse accessory olfactory bulb does not depend on disinhibition of mitral cells.

The olfactory bulb differs from other brain regions by its use of bidirectional synaptic transmission at dendrodendritic reciprocal synapses. These reciprocal synapses provide tight coupling of inhibitory feedback from granule cell interneurons to mitral cell projection neurons in the accessory olfactory bulb (AOB), at the first stage of vomeronasal processing. It has been proposed that both the mGluR2 agonist DCG-IV and noradrenaline promote mate recognition memory formation by reducing GABAergic feedback on mitral cells. The resultant mitral cell disinhibition is thought to induce a long-lasting enhancement in the gain of inhibitory feedback from granule to mitral cells, which selectively gates the transmission of the learned chemosensory information. However, we found that local infusions of both noradrenaline and DCG-IV failed to disinhibit AOB neural activity in urethane-anaesthetised mice. DCG-IV infusion had similar effects to the GABA(A) agonist isoguvacine, suggesting that it increased GABAergic inhibition in the AOB rather than reducing it. Noradrenaline infusion into the AOB also failed to disinhibit mitral cells in awake mice despite inducing long-term increases in power of AOB local field potentials, similar to those observed following memory formation. These results suggest that mitral cell disinhibition is not essential for the neural changes in the AOB that underlie mate recognition memory formation in mice.

Small doses of morphine can enhance NK cell cytotoxicity in pigs.

The effect of small and moderate doses of morphine (MF) on NK cell lytic activity (cytotoxicity, NKCC) ((51)Cr release test) and the number of circulating large granular lymphocytes (LGL) was evaluated in i.v. catheterized Pietrain crossbred pigs. Simultaneously, plasma cortisol (COR) (RIA method) was measured. Blood samples were collected 15, 60, 120, 180, and 240 min after i.v. injections of 0.5, 1.0 and 5.0 mg/kg of MF alone or MF pretreated with naloxone (NX, 1.0 mg/kg, i.v., 15 min before MF). It was found that MF induced dose- and time-dependent changes of NKCC. MF in a dose of 0.5 mg/kg evoked 4-fold increase in NKCC (in comparison to saline) without changes in the number of LGL/NK cells. Higher MF doses (1.0, 5.0 mg/kg) induced an early increase (up to 300Delta% and 29Delta%, respectively) followed by a decrease in cytotoxicity (to -76Delta% after 5.0 mg/kg), and in LGL number (-36Delta% after 5.0 mg/kg). These effects were concomitant with a marked rise in plasma COR (up to 234Delta% after 0.5 mg/kg and 567Delta% after 5.0 mg/kg of MF). NX pretreatment blocked all the changes in cytotoxicity but not in the LGL cell number and COR concentrations. The results indicate that MF, besides having well known immunosuppressive effects, can also enhance NKCC through the opioid receptors-dependent manner. The enhancement of cytotoxicity appears as a purely functional change independent of the recirculation of NK cells which occurs despite the high plasma concentrations of COR.

Modulation of hippocampal theta rhythm by the opioid system of the pedunculopontine tegmental nucleus.

The pedunculopontine tegmental nucleus (PPN) belongs to the brainstem system which synchronizes hippocampal activity. Theta relevant intra-PPN circuitry involves its cholinergic, GABA-ergic and glutamatergic neurons and Substance P as neuromodulator. Evidence that PPN opioid elements also modulate the hippocampal theta is provided here. In urethane-anesthetized rats a unilateral microinjection of morphine (MF) (1.5 and 5 microg) increased the maximal peak power of tail pinch-induced theta. The higher dose also increased the corresponding frequency. When the theta was evoked by intra-PPN injection of carbachol (10 microg), the addition of MF (5 microg) prolonged theta latency and shortened the duration of the theta. These effects of MF were blocked by naloxone (5 microg). The results obtained suggest that the PPN opioid system can enhance or suppress the hippocampal theta depending on the actual level of PPN activation.

Activation of tachykinin system in the pedunculopontine tegmental nucleus suppresses hippocampal theta rhythm in urethane-anesthetized rats.

The pedunculopontine tegmental nucleus (PPN) is one of the reticular generators of the hippocampal theta rhythm. The PPN neuronal circuitry related to theta generation involves its cholinergic, GABA-ergic and glutamatergic components. Here we provide data indicating that the PPN tachykinin system may also be a part of this circuitry. In the experimental model of the tail-pinch elicited hippocampal theta in urethane-anesthetized rats (implanted with bilateral recording electrodes in the stratum moleculare of the upper blade of the dentate gyrus and with injection cannula unilaterally inserted into the PPN) it was found that intra-PPN microinjection of Substance P (SP) and [d-Pro2, d-Phe7, d-Trp9]-Substance P (DPDPDT) caused suppression of the theta and enhancement of the delta activity in the hippocampal EEG. Accordingly, there was approximately a 50% (SP)-70% (DPDPDT) decline of the peak power in the theta frequency range and a decrease by 0.4 Hz in the corresponding peak frequency (DPDPDT only) in both hippocampi. The circuitry through which SP exerts its effect in the PPN can be only hypothetical at present. We suggest SP-evoked activation (either direct or indirect through the glutamatergic inputs) of the GABA interneurons which may tonically inhibit PPN outputs to the other theta-relevant structures.